Data represents up to 8.5 years of follow-up and are consistent across age, dose, and genotypeBLA resubmitted to U.S. FDA in January 2026; ...
Data represents up to 8.5 years of follow-up and are consistent across age, dose, and genotype BLA resubmitted to U.S. FDA in January 2026; Company expects up to six-month review period per FDA guidel ...
Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.
Welltica+ on MSN
Study finds blood changes linked to early Parkinson’s
New research suggests that Parkinson’s disease may leave detectable traces far earlier than previously measurable.
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced ...
In recent years, technology designed to improve sleep has moved far beyond simple white-noise machines and basic ...
Transmission of Nipah virus to humans can occur from direct contact with infected animals like bats, pigs or horses, and by ...
Sanofi’s LEAP2MONO phase 3 study of venglustat to treat type 3 Gaucher disease meets all primary endpoints: Paris Tuesday, February 3, 2026, 13:00 Hrs [IST] Positive results fro ...
DEAR DR. ROACH: I am an 82-year old man who was in good health until I found out that I have an issue in my left kidney. My ...
Indian cybersecurity firm 63SATS Cybertech is positioning itself at the intersection of AI adoption and trust, focusing on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results